2-c]quinoline-6,7,8,13-tetraones 5a,b and 6, as potential ERK inhibitors. New inhibitors were synthesized and identified by different spectroscopic techniques and X-ray crystallography. They were evaluated for their ability to inhibit ERK1/2 in an in vitro radioactive kinase assay. 3b and 6 inhibited ERK1 with IC50s of 0.5 and 0.19 µM, and inhibited ERK2 with IC50s of 0.6 and 0.16 µM respectively. Kinetic
大约60%的人类癌症表现出增强的ERK1和ERK2活性,反映了它们在肿瘤发生和发展中的多重作用。获得性抗药性,特别是与
MAPK激活(RAF / MEK / ERK)通路相关的机制,代表了目前对黑素瘤和其他几种癌症治疗的重大挑战。最近,针对ERK的发展已成为克服这一阻力的潜在诱人策略。在此,我们报告了一系列新颖的融合
萘酚呋喃并[3,2-c]
喹啉-6,7,12-三酮3a-f和
吡喃并[3,2-c]
喹啉-6,7,8, 13-四酮5a,b和6,作为潜在的ERK
抑制剂。合成了新的
抑制剂,并通过不同的光谱技术和X射线晶体学对其进行了鉴定。在体外放射性激酶测定中评估了它们抑制ERK1 / 2的能力。3b和6分别以0.5和0.19 µM的IC50抑制ERK1,并以0.6和0.16 µM的IC50抑制ERK2。动力学机理研究表明,这些
抑制剂是
ATP竞争性
抑制剂,其中6种抑制ERK2的Ki为0.09 µM。测试